Incyte

A clinical trial at WashU Medicine showed that adding itacitinib to standard care for 'half-matched' stem cell transplants may reduce graft-versus-host disease, with no severe cases observed in 42 patients.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

Navitoclax (AbbVie) combined with ruxolitinib (Jakafi; Incyte Corp) showed durable responses and potential disease modification in relapsed/refractory myelofibrosis (MF) in the phase 2 REFINE trial. The combination therapy demonstrated favorable reductions in spleen volume and overall symptoms, with a 39% SVR35 rate and 46% TSS50 rate at any time on study. BMF improved by ≥1 grade in 39% of patients, and 23% achieved an anemia response. The most common adverse event was thrombocytopenia, manageable with dose adjustment.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.

Investing in biotech ETFs like iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT) offers exposure to healthcare innovations. The global biotech market is expected to reach $4.61 trillion by 2034, driven by aging populations and increased healthcare spending. ETFs allow investors to benefit from industry growth while managing risk.

The hidradenitis suppurativa market is projected to grow at a CAGR of 12.4% by 2034, driven by increased awareness, treatment access, biologic therapy approvals, and a robust pipeline. The market size in the 7MM was USD 1.4 billion in 2023, with approximately 6.2 million prevalent cases. Key companies and treatments include Incyte Corporation, AbbVie, MoonLake Immunotherapeutics, and therapies like Povorcitinib, RINVOQ, Lutikizumab, and Sonelokimab. Regulatory milestones and clinical trials are advancing, with potential market shifts expected from emerging therapies.

The atopic dermatitis market is projected to grow from $7.51 billion in 2023 to $15.27 billion by 2028, driven by advancements in biologic therapies, personalized medicine, and product innovations. Key players include Sanofi SA, Regeneron Pharmaceuticals Inc., and Novartis International AG.

DelveInsight's 'Glioblastoma Pipeline Insight, 2024' report details 190+ companies developing 200+ therapies, including Enzastaurin, Marizomib, VT1021, and ONC201, with insights on mechanism of action, route of administration, and market dynamics.

Regeneron Pharmaceuticals is compared against key competitors in the Biotechnology industry, revealing lower P/E, P/B, and P/S ratios suggesting potential undervaluation, but a low ROE indicating lower profitability efficiency. High EBITDA and gross profit levels show strong operational performance, while low revenue growth may be a concern.